Abstract library

497 results for "Lowe".
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
#1743 FOLFIRI Regimen with or without Bevacizumab As Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma
Introduction: Metastatic disease of GEP-NEC is tough condition in clinical practice. And the role of the second-line therapy remains unknown
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: ASS PROF Zhiyu Chen
Authors: Chen Z, Zhao X, Wang C, Zhang W, ...
Keywords: NEC, FOLFIRI, bevacizumab
#923 A Case Report of a Pancreatic Neuroendocrine Tumor (pNET) With High Levels of 5-HIAA in Urine
Introduction: A 79-year-old man presented with weakness and weight loss. Clinical examination revealed a palpable liver and CT scan a mass in the head of pancreas and multiple liver lesions.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Nikolaos Tsoukalas
Keywords: 5-HIAA, pancreas, pNET
#1055 Neuroendocrine Pancreatic Tumor Associated with a Cerebral Neurofibroma. A Case Report.
Introduction: Neuroendocrine pancreatic tumors (pNET) are rare in young patients. They usually occur in the setting of genetic syndromes.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Doctor Valbona Lico
#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report
Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Juan Manuel O'Connor
#1464 A Case of Multiple Pancreatic Insulinoma Laparoscopically Resected through Precise Spatial Diagnosis by SACI Test
Introduction: Case: A 58-year-old man representing cold sweat, palpitation and nausea was admitted to our hospital and was pointed out parathyroid, pancreatic and superior mediastinal masses with CT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Sato A, Ito T, ...
#2002 Pulmonary Function Test Physiology and Progression in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition characterised by a generalised proliferation of pulmonary neuroendocrine cells within the respiratory epithelium. Little is known of its affects on pulmonary function both at the time of diagnosis and prospectively.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Joseph Barlow
Authors: Barlow J, Ryan D, Mansoor W, Howell M, ...
#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Gitte Dam
Keywords: gep-net, ct, cga, correlation
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#69 Frequent biological association of Merkel cell polyomavirus with Merkel cell carcinomas
Introduction: Merkel cell polyomavirus (MCPyV) DNA has been detected by PCR in 75–100% of Merkel cell carcinomas (MCC), an aggressive neuroendocrine skin cancer. MCPyV is a 5.4 kb DNA virus that expresses tumor (T) antigen in tumor tissues.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Ernst-Jan M Speel
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.